Abstract
Little is known about the contribution of over-the-counter (OTC) aspirin to cardiovascular prophylaxis. To investigate this, a two-phase cross-sectional study was carried out in nine general practices in North Staffordshire. In the first phase, all patients with cardiovascular disease (CVD) were identified from computer searches using morbidity registers and drug searches. The search also identfied the subgroup receiving prescribed prophylactic aspirin. In the second phase, a questionnaire was posted to all patients with CVD who were not on prescribed aspirin to establish their current use of OTC aspirin. Overall, 69% of the CVD group used aspirin, with 26% of aspirin being OTC. OTC aspirin use was more common in those aged under 65 years, men, and the more affluent. Also, there were significant differences in OTC aspirin use between the various practices. This study shows that a considerable amount of aspirin is used OTC in those with CVD. Its use is influenced by several factors that could be addressed when considering attempts to improve the overall uptake of aspirin.
Full Text
The Full Text of this article is available as a PDF (57.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Campbell N. C., Thain J., Deans H. G., Ritchie L. D., Rawles J. M. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ. 1998 May 9;316(7142):1430–1434. doi: 10.1136/bmj.316.7142.1430. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eccles M., Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ. 1991 Jan 12;302(6768):91–92. doi: 10.1136/bmj.302.6768.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hopper S., Pierce M. Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract. 1998 Apr;15 (Suppl 1):S10–S13. [PubMed] [Google Scholar]
- Krumholz H. M., Radford M. J., Ellerbeck E. F., Hennen J., Meehan T. P., Petrillo M., Wang Y., Jencks S. F. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996 Feb 1;124(3):292–298. doi: 10.7326/0003-4819-124-3-199602010-00002. [DOI] [PubMed] [Google Scholar]
- Richardson J., Truman C. An audit of discharge medication for secondary prophylaxis post-myocardial infarction. J Clin Pharm Ther. 1996 Dec;21(6):413–416. doi: 10.1111/j.1365-2710.1996.tb00040.x. [DOI] [PubMed] [Google Scholar]
- Smith J., Channer K. S. Increasing prescription of drugs for secondary prevention after myocardial infarction. BMJ. 1995 Oct 7;311(7010):917–918. doi: 10.1136/bmj.311.7010.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whitford D. L., Southern A. J. Audit of secondary prophylaxis after myocardial infarction. BMJ. 1994 Nov 12;309(6964):1268–1269. doi: 10.1136/bmj.309.6964.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]